-$0.08 Earnings Per Share Expected for ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) This Quarter

Share on StockTwits

Wall Street brokerages expect ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) to post earnings of ($0.08) per share for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for ZIOPHARM Oncology’s earnings, with the highest EPS estimate coming in at ($0.07) and the lowest estimate coming in at ($0.09). ZIOPHARM Oncology reported earnings of ($0.12) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 33.3%. The firm is scheduled to issue its next quarterly earnings results on Wednesday, August 14th.

On average, analysts expect that ZIOPHARM Oncology will report full year earnings of ($0.33) per share for the current year, with EPS estimates ranging from ($0.33) to ($0.32). For the next year, analysts expect that the business will report earnings of ($0.18) per share, with EPS estimates ranging from ($0.30) to $0.05. Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that that provide coverage for ZIOPHARM Oncology.

ZIOPHARM Oncology (NASDAQ:ZIOP) last released its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($0.08) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.09) by $0.01.

ZIOP has been the subject of several recent analyst reports. Zacks Investment Research upgraded Zurich Insurance Group from a “sell” rating to a “hold” rating in a research note on Saturday, May 18th. Laidlaw initiated coverage on ZIOPHARM Oncology in a research note on Monday, April 1st. They issued a “buy” rating and a $7.50 price target for the company. Lake Street Capital set a $30.00 price target on TheStreet and gave the company a “buy” rating in a research note on Thursday, April 4th. HC Wainwright lifted their price target on Palatin Technologies from $5.00 to $6.00 and gave the company a “buy” rating in a research note on Thursday, May 9th. Finally, BidaskClub upgraded ZIOPHARM Oncology from a “buy” rating to a “strong-buy” rating in a research note on Monday, June 17th. One analyst has rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $5.75.

Shares of NASDAQ ZIOP traded down $0.02 during trading on Wednesday, reaching $5.69. 8,080 shares of the company traded hands, compared to its average volume of 2,554,339. The company has a fifty day moving average price of $5.15. The firm has a market cap of $921.13 million, a PE ratio of -11.91 and a beta of 2.66. ZIOPHARM Oncology has a 12-month low of $1.56 and a 12-month high of $6.30. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.89 and a current ratio of 8.89.

A number of large investors have recently bought and sold shares of the business. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its stake in ZIOPHARM Oncology by 12.3% during the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 52,871 shares of the biotechnology company’s stock worth $204,000 after buying an additional 5,802 shares in the last quarter. Legal & General Group Plc boosted its holdings in shares of ZIOPHARM Oncology by 30.6% during the 4th quarter. Legal & General Group Plc now owns 25,865 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 6,054 shares during the last quarter. SG Americas Securities LLC boosted its holdings in shares of ZIOPHARM Oncology by 30.8% during the 1st quarter. SG Americas Securities LLC now owns 31,906 shares of the biotechnology company’s stock worth $123,000 after purchasing an additional 7,506 shares during the last quarter. Northern Trust Corp boosted its holdings in shares of ZIOPHARM Oncology by 0.5% during the 4th quarter. Northern Trust Corp now owns 1,647,754 shares of the biotechnology company’s stock worth $3,081,000 after purchasing an additional 8,068 shares during the last quarter. Finally, Harel Insurance Investments & Financial Services Ltd. acquired a new position in shares of ZIOPHARM Oncology during the 1st quarter worth approximately $35,000. Institutional investors own 38.75% of the company’s stock.

About ZIOPHARM Oncology

ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to attack cancer cells.

Featured Story: How are the companies in the S&P 500 selected?

Get a free copy of the Zacks research report on ZIOPHARM Oncology (ZIOP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Avaya  Earns “Buy” Rating from Northland Securities
Avaya Earns “Buy” Rating from Northland Securities
Bloom Energy  Earns Overweight Rating from KeyCorp
Bloom Energy Earns Overweight Rating from KeyCorp
Bristol-Myers Squibb  Lifted to “Overweight” at Atlantic Securities
Bristol-Myers Squibb Lifted to “Overweight” at Atlantic Securities
Argus Boosts AstraZeneca  Price Target to $50.00
Argus Boosts AstraZeneca Price Target to $50.00
JPMorgan Chase & Co. Raises Agnico Eagle Mines  Price Target to $83.00
JPMorgan Chase & Co. Raises Agnico Eagle Mines Price Target to $83.00
Deutsche Bank Reaffirms “Buy” Rating for Ashford Hospitality Trust
Deutsche Bank Reaffirms “Buy” Rating for Ashford Hospitality Trust


© 2006-2019 Ticker Report